Skip to main content
PMC home page
The BMJ logoLink to The BMJ
. 1992 Oct 17;305(6859):913–920. doi: 10.1136/bmj.305.6859.913

Low molecular weight heparin in prevention of perioperative thrombosis.

A Leizorovicz 1, M C Haugh 1, F R Chapuis 1, M M Samama 1, J P Boissel 1
PMCID: PMC1883560  PMID: 1281030

Abstract

OBJECTIVE--To determine whether prophylactic treatment with low molecular weight heparin reduces the incidence of thrombosis in patients who have had general or orthopaedic surgery. DESIGN--Meta-analysis of results from 52 randomised, controlled clinical studies (29 in general surgery and 23 in orthopaedic surgery) in which low molecular weight heparin was compared with placebo, dextran, or unfractionated heparin. SUBJECTS--Patients who had had general or orthopaedic surgery. INTERVENTION--Once daily injection of a low molecular weight heparin compared with placebo, dextran, or unfractionated heparin. MAIN OUTCOME MEASURES--Incidence of deep venous thrombosis, pulmonary embolism, major haemorrhages, and death. RESULTS--The results confirm that low molecular weight heparins are more efficacious for the prophylactic treatment of deep venous thrombosis than placebo (common odds ratio 0.31, 95% confidence interval 0.22 to 0.43; p < 0.001) and dextran (0.44, 0.30 to 0.65; p < 0.001). The results suggest that low molecular weight heparins are also more efficacious than unfractionated heparin (0.85, 0.74 to 0.97; p = 0.02), with no significant difference in the incidence of major haemorrhages (1.06, 0.93 to 1.20; p = 0.62). CONCLUSIONS--Low molecular weight heparins seem to have a higher benefit to risk ratio than unfractionated heparin in preventing perioperative thrombosis. However, it remains to be shown in a suitably powered clinical trial whether low molecular weight heparin reduces the risk of fatal pulmonary embolism compared with heparin.

Full text

PDF
913

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adolf J., Knee H., Roder J. D., van de Flierdt E., Siewert J. R. Thromboembolieprophylaxe mit niedermolekularem Heparin in der Abdominalchirurgie. Dtsch Med Wochenschr. 1989 Jan 13;114(2):48–53. doi: 10.1055/s-2008-1066550. [DOI] [PubMed] [Google Scholar]
  2. Baumgartner A., Jacot N., Moser G., Krähenbühl B. Prevention of postoperative deep vein thrombosis by one daily injection of low molecular weight heparin and dihydroergotamine. Vasa. 1989;18(2):152–156. [PubMed] [Google Scholar]
  3. Bergqvist D., Burmark U. S., Frisell J., Hallbök T., Lindblad B., Risberg B., Törngren S., Wallin G. Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis. Br J Surg. 1986 Mar;73(3):204–208. doi: 10.1002/bjs.1800730316. [DOI] [PubMed] [Google Scholar]
  4. Bergqvist D. Dextran in the prophylaxis of deep-vein thrombosis. JAMA. 1987 Jul 17;258(3):324–325. [PubMed] [Google Scholar]
  5. Bergqvist D., Mätzsch T., Burmark U. S., Frisell J., Guilbaud O., Hallbök T., Horn A., Lindhagen A., Ljungnér H., Ljungström K. G. Low molecular weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis. Br J Surg. 1988 Sep;75(9):888–891. doi: 10.1002/bjs.1800750920. [DOI] [PubMed] [Google Scholar]
  6. Boissel J. P., Bossard N. Registry of multicenter clinical trials. Eleventh report--1989. Thromb Haemost. 1991 Sep 2;66(3):368–383. [PubMed] [Google Scholar]
  7. Boissel J. P., Sacks H. S., Leizorovicz A., Blanchard J., Panak E., Peyrieux J. C. Meta-analysis of clinical trials: summary of an international conference. Eur J Clin Pharmacol. 1988;34(6):535–538. doi: 10.1007/BF00615213. [DOI] [PubMed] [Google Scholar]
  8. Borstad E., Urdal K., Handeland G., Abildgaard U. Comparison of low molecular weight heparin vs. unfractionated heparin in gynecological surgery. Acta Obstet Gynecol Scand. 1988;67(2):99–103. doi: 10.3109/00016348809004178. [DOI] [PubMed] [Google Scholar]
  9. Briel R. C., Doller P., Hermann C. P. Thromboembolie-Prophylaxe bei Hysterektomien mit dem niedermolekularen Heparin Fragmin. Geburtshilfe Frauenheilkd. 1988 Mar;48(3):160–164. doi: 10.1055/s-2008-1035716. [DOI] [PubMed] [Google Scholar]
  10. Buchanan M. R., Boneu B., Ofosu F., Hirsh J. The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin. Blood. 1985 Jan;65(1):198–201. [PubMed] [Google Scholar]
  11. Cade J. F., Buchanan M. R., Boneu B., Ockelford P., Cater C. J., Cerskus A. L., Hirsh J. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation. Thromb Res. 1984 Sep 15;35(6):613–625. doi: 10.1016/0049-3848(84)90265-2. [DOI] [PubMed] [Google Scholar]
  12. Caen J. P. A randomized double-blind study between a low molecular weight heparin Kabi 2165 and standard heparin in the prevention of deep vein thrombosis in general surgery. A French multicenter trial. Thromb Haemost. 1988 Apr 8;59(2):216–220. [PubMed] [Google Scholar]
  13. Carter C. J., Kelton J. G., Hirsh J., Cerskus A., Santos A. V., Gent M. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood. 1982 Jun;59(6):1239–1245. [PubMed] [Google Scholar]
  14. Chiapuzzo E., Orengo G. B., Ottria G., Chiapuzzo A., Palazzini E., Fusillo M. The use of low molecular weight heparins for postsurgical deep vein thrombosis prevention in orthopaedic patients. J Int Med Res. 1988 Sep-Oct;16(5):359–366. doi: 10.1177/030006058801600505. [DOI] [PubMed] [Google Scholar]
  15. Cicero R., del Vecchyo C., Porter J. K., Carreño J. Open window thoracostomy and plastic surgery with muscle flaps in the treatment of chronic empyema. Chest. 1986 Mar;89(3):374–377. doi: 10.1378/chest.89.3.374. [DOI] [PubMed] [Google Scholar]
  16. Colditz G. A., Tuden R. L., Oster G. Rates of venous thrombosis after general surgery: combined results of randomised clinical trials. Lancet. 1986 Jul 19;2(8499):143–146. doi: 10.1016/s0140-6736(86)91955-0. [DOI] [PubMed] [Google Scholar]
  17. Collet J. P., Boissel J. P. Sick population--treated population: the need for a better definition. The VALIDATA Group. Eur J Clin Pharmacol. 1991;41(4):267–271. doi: 10.1007/BF00314951. [DOI] [PubMed] [Google Scholar]
  18. Collins R., Scrimgeour A., Yusuf S., Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med. 1988 May 5;318(18):1162–1173. doi: 10.1056/NEJM198805053181805. [DOI] [PubMed] [Google Scholar]
  19. Dechavanne M., Ville D., Berruyer M., Trepo F., Dalery F., Clermont N., Lerat J. L., Moyen B., Fischer L. P., Kher A. Randomized trial of a low-molecular-weight heparin (Kabi 2165) versus adjusted-dose subcutaneous standard heparin in the prophylaxis of deep-vein thrombosis after elective hip surgery. Haemostasis. 1989;19(1):5–12. doi: 10.1159/000215882. [DOI] [PubMed] [Google Scholar]
  20. Dickersin K. Report from the panel on the Case for Registers of Clinical Trials at the Eighth Annual Meeting of the Society for Clinical Trials. Control Clin Trials. 1988 Mar;9(1):76–81. doi: 10.1016/0197-2456(88)90010-4. [DOI] [PubMed] [Google Scholar]
  21. Easterbrook P. J., Berlin J. A., Gopalan R., Matthews D. R. Publication bias in clinical research. Lancet. 1991 Apr 13;337(8746):867–872. doi: 10.1016/0140-6736(91)90201-y. [DOI] [PubMed] [Google Scholar]
  22. Eriksson B. I., Zachrisson B. E., Teger-Nilsson A. C., Risberg B. Thrombosis prophylaxis with low molecular weight heparin in total hip replacement. Br J Surg. 1988 Nov;75(11):1053–1057. doi: 10.1002/bjs.1800751104. [DOI] [PubMed] [Google Scholar]
  23. Esquivel C. O., Bergqvist D., Björck C. G., Nilsson B. Comparison between commercial heparin, low molecular weight heparin and pentosan polysulfate on hemostasis and platelets in vivo. Thromb Res. 1982 Nov 1;28(3):389–399. doi: 10.1016/0049-3848(82)90120-7. [DOI] [PubMed] [Google Scholar]
  24. Fricker J. P., Vergnes Y., Schach R., Heitz A., Eber M., Grunebaum L., Wiesel M. L., Kher A., Barbier P., Cazenave J. P. Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery. Eur J Clin Invest. 1988 Dec;18(6):561–567. doi: 10.1111/j.1365-2362.1988.tb01268.x. [DOI] [PubMed] [Google Scholar]
  25. Frydman A. M., Bara L., Le Roux Y., Woler M., Chauliac F., Samama M. M. The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol. 1988 Jul;28(7):609–618. doi: 10.1002/j.1552-4604.1988.tb03184.x. [DOI] [PubMed] [Google Scholar]
  26. Haas S., Stemberger A., Fritsche H. M., Welzel D., Wolf H., Lechner F., Blümel G. Prophylaxis of deep vein thrombosis in high risk patients undergoing total hip replacement with low molecular weight heparin plus dihydroergotamine. Arzneimittelforschung. 1987 Jul;37(7):839–843. [PubMed] [Google Scholar]
  27. Hartl P., Brücke P., Dienstl E., Vinazzer H. Prophylaxis of thromboembolism in general surgery: comparison between standard heparin and Fragmin. Thromb Res. 1990 Feb 15;57(4):577–584. doi: 10.1016/0049-3848(90)90074-m. [DOI] [PubMed] [Google Scholar]
  28. Heilmann L., Kruck M., Schindler A. E. Thromboseprophylaxe in der Gynäkologie: Doppelblind-Vergleich zwischen niedermolekularem (LMWH) und unfraktioniertem (UFH) Heparin. Geburtshilfe Frauenheilkd. 1989 Sep;49(9):803–807. doi: 10.1055/s-2008-1036089. [DOI] [PubMed] [Google Scholar]
  29. Hirsh J. From unfractionated heparins to low molecular weight heparins. Acta Chir Scand Suppl. 1990;556:42–50. [PubMed] [Google Scholar]
  30. Hoffmann R., Largiadèr F., Roethlin M. Perioperative Thromboembolie-Prophylaxe: niedrig dosiertes Heparin oder low molecular Heparin-DHE, Vor- und Nachteile. Eine prospektive, randomisierte Untersuchung. Helv Chir Acta. 1987 Dec;54(4):521–525. [PubMed] [Google Scholar]
  31. Kakkar V. V., Murray W. J. Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: a co-operative study. Br J Surg. 1985 Oct;72(10):786–791. doi: 10.1002/bjs.1800721006. [DOI] [PubMed] [Google Scholar]
  32. Kakkar V. V. Prevention of venous thromboembolism. Clin Haematol. 1981 Jun;10(2):543–582. [PubMed] [Google Scholar]
  33. Kakkar V. V., Stringer M. D., Hedges A. R., Parker C. J., Welzel D., Ward V. P., Sanderson R. M., Cooper D., Kakkar S. Fixed combinations of low-molecular weight or unfractionated heparin plus dihydroergotamine in the prevention of postoperative deep vein thrombosis. Am J Surg. 1989 Apr;157(4):413–418. doi: 10.1016/0002-9610(89)90589-8. [DOI] [PubMed] [Google Scholar]
  34. Koller M., Schoch U., Buchmann P., Largiadèr F., von Felten A., Frick P. G. Low molecular weight heparin (KABI 2165) as thromboprophylaxis in elective visceral surgery. A randomized, double-blind study versus unfractionated heparin. Thromb Haemost. 1986 Dec 15;56(3):243–246. [PubMed] [Google Scholar]
  35. Lane D. A., Denton J., Flynn A. M., Thunberg L., Lindahl U. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J. 1984 Mar 15;218(3):725–732. doi: 10.1042/bj2180725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Lassen M. R., Borris L. C., Christiansen H. M., Møller-Larsen F., Knudsen V. E., Boris P., Nehen A. M., Jurik A. G., de Carvalho A., Nielsen B. W. Prevention of thromboembolism in hip-fracture patients. Comparison of low-dose heparin and low-molecular-weight heparin combined with dihydroergotamine. Arch Orthop Trauma Surg. 1989;108(1):10–13. doi: 10.1007/BF00934150. [DOI] [PubMed] [Google Scholar]
  37. Lassen M. R., Borris L. C., Christiansen H. M., Møller-Larsen F., Knudsen V. E., Boris P., Nehen A. M., de Carvalho A., Jurik A. G., Nielsen B. W. Heparin/dihydroergotamine for venous thrombosis prophylaxis: comparison of low-dose heparin and low molecular weight heparin in hip surgery. Br J Surg. 1988 Jul;75(7):686–689. doi: 10.1002/bjs.1800750720. [DOI] [PubMed] [Google Scholar]
  38. Leyvraz P. F., Bachmann F., Hoek J., Büller H. R., Postel M., Samama M., Vandenbroek M. D. Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. BMJ. 1991 Sep 7;303(6802):543–548. doi: 10.1136/bmj.303.6802.543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Leyvraz P. F., Richard J., Bachmann F., Van Melle G., Treyvaud J. M., Livio J. J., Candardjis G. Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med. 1983 Oct 20;309(16):954–958. doi: 10.1056/NEJM198310203091605. [DOI] [PubMed] [Google Scholar]
  40. Lieberman J., Winter B., Sastre A. Alpha 1-antitrypsin Pi-types in 965 COPD patients. Chest. 1986 Mar;89(3):370–373. doi: 10.1378/chest.89.3.370. [DOI] [PubMed] [Google Scholar]
  41. Liezorovicz A., Picolet H., Peyrieux J. C., Boissel J. P. Prevention of perioperative deep vein thrombosis in general surgery: a multicentre double blind study comparing two doses of Logiparin and standard heparin. H.B.P.M. Research Group. Br J Surg. 1991 Apr;78(4):412–416. doi: 10.1002/bjs.1800780410. [DOI] [PubMed] [Google Scholar]
  42. Lockner D., Bratt G., Törnebohm E., Aberg W. Pharmacokinetics of intravenously and subcutaneously administered Fragmin in healthy volunteers. Haemostasis. 1986;16 (Suppl 2):8–10. doi: 10.1159/000215349. [DOI] [PubMed] [Google Scholar]
  43. Monreal M., Lafoz E., Navarro A., Granero X., Caja V., Caceres E., Salvador R., Ruiz J. A prospective double-blind trial of a low molecular weight heparin once daily compared with conventional low-dose heparin three times daily to prevent pulmonary embolism and venous thrombosis in patients with hip fracture. J Trauma. 1989 Jun;29(6):873–875. doi: 10.1097/00005373-198906000-00028. [DOI] [PubMed] [Google Scholar]
  44. Mätzsch T., Bergqvist D., Fredin H., Hedner U. Safety and efficacy of a low molecular weight heparin (Logiparin) versus dextran as prophylaxis against thrombosis after total hip replacement. Acta Chir Scand Suppl. 1988;543:80–84. [PubMed] [Google Scholar]
  45. Ockelford P. A., Patterson J., Johns A. S. A double-blind randomized placebo controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low molecular weight heparin fragment (Fragmin). Thromb Haemost. 1989 Dec 29;62(4):1046–1049. [PubMed] [Google Scholar]
  46. Onarheim H., Lund T., Heimdal A., Arnesjø B. A low molecular weight heparin (KABI 2165) for prophylaxis of postoperative deep venous thrombosis. Acta Chir Scand. 1986 Oct;152:593–596. [PubMed] [Google Scholar]
  47. Pini M., Tagliaferri A., Manotti C., Lasagni F., Rinaldi E., Dettori A. G. Low molecular weight heparin (Alfa LHWH) compared with unfractionated heparin in prevention of deep-vein thrombosis after hip fractures. Int Angiol. 1989 Jul-Sep;8(3):134–139. [PubMed] [Google Scholar]
  48. Planes A., Vochelle N., Mazas F., Mansat C., Zucman J., Landais A., Pascariello J. C., Weill D., Butel J. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost. 1988 Dec 22;60(3):407–410. [PubMed] [Google Scholar]
  49. Samama M., Bernard P., Bonnardot J. P., Combe-Tamzali S., Lanson Y., Tissot E. Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. Br J Surg. 1988 Feb;75(2):128–131. doi: 10.1002/bjs.1800750213. [DOI] [PubMed] [Google Scholar]
  50. Sasahara A. A., Koppenhagen K., Häring R., Welzel D., Wolf H. Low molecular weight heparin plus dihydroergotamine for prophylaxis of postoperative deep vein thrombosis. Br J Surg. 1986 Sep;73(9):697–700. doi: 10.1002/bjs.1800730906. [DOI] [PubMed] [Google Scholar]
  51. Schmitz-Huebner U., Bünte H., Freise G., Reers B., Rüschemeyer C., Scherer R., Schulte H., van de Loo J. Clinical efficacy of low molecular weight heparin in postoperative thrombosis prophylaxis. Klin Wochenschr. 1984 Apr 16;62(8):349–353. doi: 10.1007/BF01716253. [DOI] [PubMed] [Google Scholar]
  52. Simes R. J. Confronting publication bias: a cohort design for meta-analysis. Stat Med. 1987 Jan-Feb;6(1):11–29. doi: 10.1002/sim.4780060104. [DOI] [PubMed] [Google Scholar]
  53. Simes R. J. Publication bias: the case for an international registry of clinical trials. J Clin Oncol. 1986 Oct;4(10):1529–1541. doi: 10.1200/JCO.1986.4.10.1529. [DOI] [PubMed] [Google Scholar]
  54. Taberner D. A., Poller L., Thomson J. M., Lemon G., Weighill F. J. Randomized study of adjusted versus fixed low dose heparin prophylaxis of deep vein thrombosis in hip surgery. Br J Surg. 1989 Sep;76(9):933–935. doi: 10.1002/bjs.1800760920. [DOI] [PubMed] [Google Scholar]
  55. Thompson S. G., Pocock S. J. Can meta-analyses be trusted? Lancet. 1991 Nov 2;338(8775):1127–1130. doi: 10.1016/0140-6736(91)91975-z. [DOI] [PubMed] [Google Scholar]
  56. Turpie A. G., Levine M. N., Hirsh J., Carter C. J., Jay R. M., Powers P. J., Andrew M., Hull R. D., Gent M. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med. 1986 Oct 9;315(15):925–929. doi: 10.1056/NEJM198610093151503. [DOI] [PubMed] [Google Scholar]
  57. Tørholm C., Broeng L., Jørgensen P. S., Bjerregaard P., Josephsen L., Jørgensen P. K., Hagen K., Knudsen J. B. Thromboprophylaxis by low-molecular-weight heparin in elective hip surgery. A placebo controlled study. J Bone Joint Surg Br. 1991 May;73(3):434–438. doi: 10.1302/0301-620X.73B3.1670445. [DOI] [PubMed] [Google Scholar]
  58. Valle I., Sola G., Origone A. Controlled clinical study of the efficacy of a new low molecular weight heparin administered subcutaneously to prevent post-operative deep venous thrombosis. Curr Med Res Opin. 1988;11(2):80–86. doi: 10.1185/03007998809110450. [DOI] [PubMed] [Google Scholar]
  59. Verardi S., Casciani C. U., Nicora E., Forzano F., Origone A., Valle I., Catania G., Salanitri G., Salcuni P., Azzarone M. A multicentre study on LMW-heparin effectiveness in preventing postsurgical thrombosis. Int Angiol. 1988 Jul-Sep;7(3 Suppl):19–24. [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES